Arnulf Stenzl

36.4k total citations · 8 hit papers
893 papers, 22.1k citations indexed

About

Arnulf Stenzl is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Urology. According to data from OpenAlex, Arnulf Stenzl has authored 893 papers receiving a total of 22.1k indexed citations (citations by other indexed papers that have themselves been cited), including 427 papers in Surgery, 324 papers in Pulmonary and Respiratory Medicine and 252 papers in Urology. Recurrent topics in Arnulf Stenzl's work include Bladder and Urothelial Cancer Treatments (289 papers), Urological Disorders and Treatments (212 papers) and Urinary and Genital Oncology Studies (190 papers). Arnulf Stenzl is often cited by papers focused on Bladder and Urothelial Cancer Treatments (289 papers), Urological Disorders and Treatments (212 papers) and Urinary and Genital Oncology Studies (190 papers). Arnulf Stenzl collaborates with scholars based in Germany, United States and Austria. Arnulf Stenzl's co-authors include Jörg Hennenlotter, Georgios Gakis, Jens Bedke, Axel S. Merseburger, David Schilling, Stephan Kruck, Karl‐Dietrich Sievert, Markus A. Kuczyk, J. Alfred Witjes and Christian Schwentner and has published in prestigious journals such as Nature, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Arnulf Stenzl

856 papers receiving 21.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer

2019 686 citations Arnulf Stenzl et al. profile →
Treatment of Muscle-invasive and Metastatic Bladder Cancer: Update of the EAU Guidelines

2011 483 citations Arnulf Stenzl, Markus A. Kuczyk et al. profile →
The Economics of Bladder Cancer: Costs and Considerations of Caring for This Disease

2014 393 citations Arnulf Stenzl et al. profile →
Economic aspects of bladder cancer: what are the benefits and costs?

2009 372 citations Bastian Amend, Jens Bedke et al. profile →
Current best practice for bladder cancer: a narrative review of diagnostics and treatments

2022 233 citations Ashish M. Kamat, Arnulf Stenzl et al. profile →
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial

2021 183 citations Arnulf Stenzl et al. profile →
Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

2022 169 citations Arnulf Stenzl et al. profile →
Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021

2021 131 citations Arnulf Stenzl et al. profile →

Peers

Countries citing papers authored by Arnulf Stenzl

Since Specialization

Citations

This map shows the geographic impact of Arnulf Stenzl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arnulf Stenzl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arnulf Stenzl more than expected).

Fields of papers citing papers by Arnulf Stenzl

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arnulf Stenzl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arnulf Stenzl. The network helps show where Arnulf Stenzl may publish in the future.

Co-authorship network of co-authors of Arnulf Stenzl

This figure shows the co-authorship network connecting the top 25 collaborators of Arnulf Stenzl. A scholar is included among the top collaborators of Arnulf Stenzl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arnulf Stenzl. Arnulf Stenzl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Potential impacts to human health from climate change: A comparative life-cycle assessment of single-use versus reusable devices flexible ureteroscopes 2024 ·Urolithiasis ·(unknown), Jan Lask, Jörg Hennenlotter, Matthias Saar, Igor Tsaur, Arnulf Stenzl, Steffen Rausch	1
2	Interleukin-1β/Interleukin (IL)-1-Receptor-Antagonist (IL1-RA) Axis in Invasive Bladder Cancer—An Exploratory Analysis of Clinical and Tumor Biological Significance 2024 ·International Journal of Molecular Sciences ·(unknown), (unknown), Jörg Hennenlotter, Tilman Todenhöfer, (unknown), (unknown), Igor Tsaur, Arnulf Stenzl, Steffen Rausch	2
3	PD-L1 Expression in High-Risk Non-Muscle-Invasive Bladder Cancer Is Influenced by Intravesical Bacillus Calmette–Guérin (BCG) Therapy 2024 ·Cancers ·Moritz Maas, (unknown), (unknown), Viktoria Stühler, Simon Walz, Steffen Rausch, Arnulf Stenzl, Igor Tsaur, Jörg Hennenlotter, Stefan Aufderklamm	5
4	Contemporary Role of Lymph Node Dissection in Genitourinary Cancers: Where Are We in 2023? 2023 ·European Urology Oncology ·(unknown), Alberto Briganti, Bradley C. Leibovich, Seth P. Lerner, Marco Moschini, Morgan Rouprêt, Shahrokh F. Shariat, Philippe E. Spiess, Arnulf Stenzl, Samir S. Taneja, Karim Touijer, Ashish M. Kamat	3
5	Protein Levels of Anti-Apoptotic Mcl-1 and the Deubiquitinase USP9x Are Cooperatively Upregulated during Prostate Cancer Progression and Limit Response of Prostate Cancer Cells to Radiotherapy 2023 ·Cancers ·(unknown), Diana Klein, (unknown), Stephan M. Huber, Jörg Hennenlotter, Arnulf Stenzl, Justine Rudner	1
6	Differential Expression and Clinical Relevance of C-X-C Motif Chemokine Receptor 4 (CXCR4) in Renal Cell Carcinomas, Benign Renal Tumors, and Metastases 2023 ·International Journal of Molecular Sciences ·Moritz Maas, (unknown), Jörg Hennenlotter, Marcus Scharpf, Falko Fend, Simon Walz, Viktoria Stühler, Tilman Todenhöfer, Arnulf Stenzl, Jens Bedke, Steffen Rausch	2
7	Differentiation of bladder cancer with water flow elastography (WaFE) 2023 ·Journal of the mechanical behavior of biomedical materials ·(unknown), Simon Walz, Massimo Granai, Falko Fend, Arnulf Stenzl, Tilman E. Schäffer	2
8	Growth of Simulated Tumors Under the Influence of Oxygen Supply 2022 ·IFAC-PapersOnLine ·(unknown), (unknown), (unknown), (unknown), Bastian Amend, Arnulf Stenzl, (unknown), (unknown), Oliver Sawodny, Cristina Tarín	1
9	Electro-Mechanical Coupling in Impedance-Based Tissue Differentiation Under Compression* 2022 ·IFAC-PapersOnLine ·(unknown), (unknown), (unknown), (unknown), (unknown), Arnulf Stenzl, Cristina Tarín, Oliver Sawodny	3
10	Elevated Expression of the Immune Checkpoint Ligand CD276 (B7-H3) in Urothelial Carcinoma Cell Lines Correlates Negatively with the Cell Proliferation 2022 ·International Journal of Molecular Sciences ·(unknown), (unknown), (unknown), (unknown), Ivonne A. Montes‐Mojarro, Falko Fend, Wilhelm K. Aicher, Arnulf Stenzl, Bastian Amend	7
11	CD24: A Marker for an Extended Expansion Potential of Urothelial Cancer Cell Organoids In Vitro? 2022 ·International Journal of Molecular Sciences ·(unknown), (unknown), Ivonne A. Montes‐Mojarro, Falko Fend, Wilhelm K. Aicher, Arnulf Stenzl, Bastian Amend	10
12	Comparison of the metabolome in urine prior and eight weeks after radical prostatectomy uncovers pathologic and molecular features of prostate cancer 2021 ·Journal of Pharmaceutical and Biomedical Analysis ·Simon Walz, Qingqing Wang, Xinjie Zhao, Miriam Hoene, Hans‐Ulrich Häring, Jörg Hennenlotter, Moritz Maas, Andreas Peter, Tilman Todenhöfer, Arnulf Stenzl, Xinyu Liu, Rainer Lehmann, Guowang Xu	3
13	Age-, tumor-, and metastatic tissue-associated DNA hypermethylation of a T-box brain 1 locus in human kidney tissue 2020 ·Clinical Epigenetics ·Jürgen Serth, Inga Peters, Natalia Dubrowinskaja, (unknown), Knut Albrecht, Michael Klintschar, Marcel Lafos, Alexander Grote, Albert J. Becker, Jörg Hennenlotter, Arnulf Stenzl, Hossein Tezval, Markus A. Kuczyk	10
14	PD-1 and LAG-3 Dominate Checkpoint Receptor–Mediated T-cell Inhibition in Renal Cell Carcinoma 2019 ·Cancer Immunology Research ·Henning Zelba, Jens Bedke, Jörg Hennenlotter, Sven Mostböck, Markus Zettl, Thomas Zichner, Anoop Chandran, Arnulf Stenzl, Hans‐Georg Rammensee, Cécile Gouttefangeas	78
15	A Subpopulation of Stromal Cells Controls Cancer Cell Homing to the Bone Marrow 2017 ·Cancer Research ·(unknown), (unknown), Christopher Groth, Eva Altrock, Franz Jakob, Sarah Schott, Pauline Wimberger, Theresa Link, Jan Dominik Kuhlmann, Arnulf Stenzl, Jörg Hennenlotter, (unknown), Markus Rojewski, Karen Bieback, Inaam A. Nakchbandi	30
16	Perioperative morbidity, bowel function and oncologic outcome after radical cystectomy and ileal orthotopic neobladder reconstruction: Studer-pouch versus I-pouch 2017 ·European Journal of Surgical Oncology ·Johannes Mischinger, (unknown), Steffen Rausch, Tilman Todenhöfer, Eva Neumann, Stefan Aufderklamm, Arnulf Stenzl, Georgios Gakis	6
17	Extracorporeal Shock Wave Therapy in Peyronie's Disease: Results of a Placebo-Controlled, Prospective, Randomized, Single-Blind Study 2013 ·The Journal of Sexual Medicine ·Georgios Hatzichristodoulou, Christoph Meisner, Jürgen E. Gschwend, Arnulf Stenzl, Sven Lahme	72
18	DNA Methylation of the SLC16A3 Promoter Regulates Expression of the Human Lactate Transporter MCT4 in Renal Cancer with Consequences for Clinical Outcome 2013 ·Clinical Cancer Research ·Pascale Fisel, Stephan Kruck, Stefan Winter, Jens Bedke, Jörg Hennenlotter, Anne T. Nies, Marcus Scharpf, Falko Fend, Arnulf Stenzl, Matthias Schwab, Elke Schaeffeler	79
19	Simultaneous Infiltration of Polyfunctional Effector and Suppressor T Cells into Renal Cell Carcinomas 2009 ·Cancer Research ·Sebastian Attig, Jörg Hennenlotter, Graham Pawelec, Gerd Klein, Sven D. Koch, Hanspeter Pircher, Susan Feyerabend, Dorothee Wernet, Arnulf Stenzl, Hans‐Georg Rammensee, Cécile Gouttefangeas	76
20	Unexpected Abundance of HLA Class II Presented Peptides in Primary Renal Cell Carcinomas 2006 ·Clinical Cancer Research ·Jörn Dengjel, Maria-Dorothea Nastke, Cécile Gouttefangeas, Gitsios Gitsioudis, Oliver Schoor, Florian Altenberend, Margret Müller, Björn Krämer, Anna Missiou, Martina Sauter, Jörg Hennenlotter, Dorothee Wernet, Arnulf Stenzl, Hans‐Georg Rammensee, Karin Klingel, Stefan Stevanović	54

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact